1.
Abstract: In the first sentence of your abstract you start with an abbreviation that is not explained (AHM). Please write this abbreviation in full the first time it is used. 2.
Introduction: You state that a low target SBP in SPRINT did not result in more orthostatic hypotension or falls. However, it did result in more hypotension, syncope, electrolyte abnormalities and acute kidney injury or failure. Are these complications no concerns regarding intensive BP treatment? 3.
Introduction: The Cochrane meta-analysis by Musini et al. reported that antihypertensive treatment in patients aged 80 and older did not reduce mortality. Why did you not mention this metaanalysis? 4.
Methods: Did both reviewers perform the interviews? Where they both present during each interview, or did they interview the GPs separately? 5.
Methods: You used semi-structured interviews. You also asked participating GPs to retrieve recent case histories on antihypertensive treatment in older patients. How did the used methodology differ from a think-aloud study? Or was it a mixedmethod approach? 6.
Methods: Why did you not use any software to analyse your data? Might this have led to bias? 7.
Results: Page 7 line 41, 'enables' should be 'enablers'? 8.
Many definitions of frailty exist. Did you ask the GPs what they meant by frailty? Is it possible that the differences in the definition of frailty have influenced your results? Please discuss. 9.
I would also suggest referring to the paper by Mermans et al. (BMC Family Practice 2016:17:122) on the treatment intentions of general practitioners regarding hypertension in the oldest old in the Discussion. As you correctly stated, there is not much literature on this topic, but I believe this paper also adds a part of the puzzle. 10.
Are the current START/STOPP criteria applicable for patients aged 80 older? Is there already enough evidence to support these criteria for the oldest old? 11.
'The needs for future support' was an important research question. However, I find the part on this topic in the discussion rather disappointing. Is it just a problem of lack of evidence? I would like you to elaborate a bit more on this topic. What should be the research agenda in the following years, and what can already be done with the current knowledge?
REVIEWER

Shannon McKinn
PhD Candidate, The University of Sydney, Australia REVIEW RETURNED 07-Feb-2018
GENERAL COMMENTS
Thank you for the opportunity to review this paper. It is an interesting topic, and one of increasing importance. My specific points for revision are as follows:
Abstract: 1. Objectives: Use of abbreviation AHM in Objectives section should be written out in full for first usage.
2.
Participants: Include number of participants here. 3.
Results: I don't find the first sentence about saturation to be necessary here, particularly if you include the number of participants in the preceding section. 4.
Sentence starting "Deprescription was facilitated when GPs had experience with increased quality…" is a bit unclear. Should be clarified that GPs had experience with *patients* experiencing increased quality of life after deprescribing. The second half of this sentence after the colon is unclear, and I think ungrammatical, as the section after the colon is not an independent clause. Do you mean to say that the anticipated regret is GPs' fear of a stroke after deprescribing? I think this would make more sense if it read "and was withheld by anticipated regret should a patient suffer a stroke after deprescribing" or something similar.
Introduction: 5.
General grammatical note -some missing possessive apostrophes. E.g. "Our primary aim was to explore GPs' routines", not "GPs routines." Methods: 6.
I am unsure as to what you mean in saying that the interviews were performed using the COREQ criteria? These are criteria for reporting qualitative research, not conducting interviews. 7.
Subheadings throughout this section would be helpful for the reader (i.e. Recruitment and sample, Data collection, Data analysis) 8.
How were GPs approached to participate? Phone, face to face, etc? As you actually have quite a high participation rate for GP research this might be useful information for readers. 9.
How does Box 1 apply to the sentence that it follows? I gather that Box 1 justifies why you have chosen to conduct this study with GPs as opposed to say, cardiologists, but this is not explicit in the sentence that introduces Box 1. 10.
Last sentence of p6 -remove word 'at', 'transcribed by the interviewer verbatim' 11.
Your COREQ checklist says that have included a statement of the theoretical framework/methodological approach on p7 but this is not discussed and should be included. The discussion of your thematic analysis process does not constitute a discussion of methodological approach, as thematic analysis can be used within many different methodologies. 12.
Was any software used in the coding process, even if it was simple software like Word and/or Excel? Or was your coding paperbased? Please specify. 13.
Last sentence is missing a word between 'this' and 'underrepresented.'
Results:
14.
Statement about saturation should be in the Methods section, and a sentence should be included stating how this was determined. 15.
First paragraph of Results, last word should be 'enablers' not 'enables. ' 16. First sentence in section titled 'Starting treatment' reads strangely. Would suggest 'reluctant to start AHM in older patients' or 'at older ages.' 17.
For quotes in text and in Box 3 -although they are likely related, I think that stating the GPs' years of practice, rather than their age may be more interesting for the reader. 18.
In section 'Continuation of treatment' what does 'global checks of AHM regimens' mean? 19.
In section 'Current guideline and future support', in the first sentence 'overthink' has a different meaning to what I believe you are implying (generally overthink has a negative meaning). I would suggest the use of 'reflect on decisions' rather than 'overthink.' 20.
The quotes used in this section are both from less experienced GPs. Was there any variation with regard to this theme between less and more experienced GPs? 21.
At the end of this section you discuss suggested ideas for future support. As these are in the Results I assume these suggestions come from your participants, could you make this explicit.
Discussion: 22.
Some issues with English expression/grammar throughout this section. Some suggested corrections 'may refrain from intensifying AHM in cases of frailty' not 'in case of frailty', 'supported by anticipated discomfort' not 'supported by the anticipating discomfort', 'Anticipated regret of a future stroke' not 'anticipated regret for stroke' (appears in both the first and final paragraphs of the Discussion) 23.
You mention the increased role of practice nurses in CVD prevention programs, could this be include as a possible avenue for future research in deprescribing practice in the Netherlands? 24.
Just a suggestion, but a paper has come out since you submitted this for review which may provide something to your discussion of patient preferences and shared decision-making in deprescribing: Weir K et al. The Journals of Gerontology 2017 https://doi.org/10.1093/geronb/gbx138 Tables and Boxes: 25.
Title of Box 3 -suggestion to change to title to 'Quotes about patient cases…' rather than 'citations…'
VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Editorial Requirements: -We believe that the details in Table 1 contain enough detail to make the participants identifiable. Please revise the table to include a maximum of two indirect identifiers (e.g., age and sex). You may wish to present the material as a range instead (e.g., age: 30-34). Thank you for letting us know the participant characteristics may be too detailed. We have changed the table from characteristics per participant to summary statistics on the entire study population (Table 1, page 21-22) . Also, in line with the suggestion of reviewer 2, we have changed the characteristics after each quote from gender and age to gender and range in years of experience to ensure anonymity of our participants.
Reviewer: 1
Reviewer Name Bert Vaes
Institution and Country KU Leuven, Belgium
Please state any competing interests or state 'None declared': None declared.
Please leave your comments for the authors below This paper explored general practitioners' routines and considerations on (de)prescribing antihypertensive medication in older patients, their judgement on usability of the current guideline and needs for future support. This is a very interesting and relevant paper, but I have a few questions.
1.
Abstract: In the first sentence of your abstract you start with an abbreviation that is not explained (AHM). Please write this abbreviation in full the first time it is used. We would like to thank the reviewer for his compliments on the topic of the paper and for noticing this error in the abstract. We have added the full wording of AHM. Page 2, lines 23-25: "Objectives -To explore general practitioners' (GPs) routines and considerations on (de)prescribing antihypertensive medication (AHM) in older patients, their judgement on usability of the current guideline and needs for future support."
2.
Introduction: You state that a low target SBP in SPRINT did not result in more orthostatic hypotension or falls. However, it did result in more hypotension, syncope, electrolyte abnormalities and acute kidney injury or failure. Are these complications no concerns regarding intensive BP treatment? These are indeed important concerns regarding intensive BP treatment. However, in the article of Williamson et al. (2016, JAMA) among SPRINT participants aged ≥75 years, the effects on all these outcome measures were not significant. We added acute kidney injury as one of the concerns regarding intensive BP treatment to the introduction. Page 5, lines 100-102: "This trial also showed that a low target SBP did not result in more orthostatic hypotension, falls or acute kidney injury, which are concerns regarding intensive BP treatment."
3.
Introduction: The Cochrane meta-analysis by Musini et al. reported that antihypertensive treatment in patients aged 80 and older did not reduce mortality. Why did you not mention this metaanalysis?
Thank you for this suggestion. We have added this information to our introduction. However, we referred to a different systematic review that was published a year later (with comparable results), as we already referred to this manuscript later in the introduction. Page 5, lines 97-98: "Overall, antihypertensive treatment in the oldest old (>80 years) seems to reduce cardiovascular morbidity, but has no effect on overall mortality."
4.
Methods: Did both reviewers perform the interviews? Where they both present during each interview, or did they interview the GPs separately? Both reviewers perform the interviews separately. We have rephrase this section somewhat to make that more clear: Page 6, lines 129-130: "Each interview was done by one of two researchers (TvM and SI), both young female physicians trained in qualitative interviewing."
5.
Methods: You used semi-structured interviews. You also asked participating GPs to retrieve recent case histories on antihypertensive treatment in older patients. How did the used methodology differ from a think-aloud study? Or was it a mixed-method approach? It does resemble a think-aloud method, however as we used these case discussions merely as a tool to aid the discussion, we did not strictly follow the think-aloud methodology. Together with the retrospective view in discussing the cases, we are somewhat reluctant in labelling it as such.
6.
Methods: Why did you not use any software to analyse your data? Might this have led to bias? We did not use any specific qualitative software, but use Microsoft word to code the manuscripts (in double) and Microsoft excel to structure our codes into themes and subthemes. This way we were able to keep an overview. Qualitative software is, to our opinion, merely a tool to aid researchers in an overview of their data and codes (at least in a qualitative study such as ours). To the best of our knowledge there is no evidence to support that not using qualitative software may lead to bias.
7.
Results: Page 7 line 41, 'enables' should be 'enablers'? Thank you for alerting us to this error. We have changed it accordingly.
8.
Many definitions of frailty exist. Did you ask the GPs what they meant by frailty? Is it possible that the differences in the definition of frailty have influenced your results? Please discuss. That was indeed one of the things we elaborated on during the interviews, however because of the large amount of data we did not elaborate on it in the results section of the manuscript. The interviewed GPs stated frailty was a subjective impression of a patient based on the way someone stands up, walks, shakes your hand etc. But it was also influenced by someone's physical and cognitive functioning and whether he/she can live independently. We have added this to the results section. Page 8, lines 168-169: "GPs evaluated frailty based on their clinical impression and physical, cognitive and overall functioning." 9.
I would also suggest referring to the paper by Mermans et al. (BMC Family Practice 2016:17:122) on the treatment intentions of general practitioners regarding hypertension in the oldest old in the Discussion. As you correctly stated, there is not much literature on this topic, but I believe this paper also adds a part of the puzzle. Thank you for pointing out this nice paper. We have included it in the discussion. Page 14, lines 323-325: "In addition, an estimation of frailty seems important which, by its subjective nature, could bring about the large variation in treatment intentions of GPs, which was previously described in a Belgian vignette study."
10.
Are the current START/STOPP criteria applicable for patients aged 80 older? Is there already enough evidence to support these criteria for the oldest old? Currently no general indicators to deprescribe antihypertensive medication are included in the STOPP/START criteria. However, if sufficient evidence would become available this might be a useful addition. As this is beyond the scope of our manuscript, which focused on GPs perspectives rather than available evidence, we propose to not further elaborate on this.
11.
'The needs for future support' was an important research question. However, I find the part on this topic in the discussion rather disappointing. Is it just a problem of lack of evidence? I would like you to elaborate a bit more on this topic. What should be the research agenda in the following years, and what can already be done with the current knowledge? As our manuscript describes a qualitative study from the GPs' perspective we chose to only mention the limited and sometimes inconsistent available evidence in the introduction and keep the discussion from a GPs' perspective. Research would, in our opinion, improve from more deprescription trials with a longer duration of follow-up (as described on page 14, lines 330-332). With current knowledge clinical practice could improve by more attention for shared decision making (as described on page 14, lines 327-328) and more structural time for medication reviews. We added this last suggestion to the discussion. Page 14, lines 319-321: "As continuation also seems to be a consequence of daily routine influenced by time constraints and automated prescription routines, over -treatment might be prevented by more structural time for medication reviews."
Reviewer: 2
Reviewer Name Shannon McKinn
Institution and Country PhD Candidate, The University of Sydney, Australia Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Thank you for the opportunity to review this paper. It is an interesting topic, and one of increasing importance. My specific points for revision are as follows:
Abstract: 1.
Objectives: Use of abbreviation AHM in Objectives section should be written out in full for first usage. We thank the reviewer for her comments and useful suggestions to improve the manuscript. It is very useful that you have noticed this minor error in the abstract. We have adjusted it accordingly (as shown previously).
2.
Participants: Include number of participants here. We have added the number of participants to this section. Page 2, lines 28-29: "Participants -Fifteen GPs were purposively sampled based on level of experience and practice characteristics until saturation was reached."
3.
Results: I don't find the first sentence about saturation to be necessary here, particularly if you include the number of participants in the preceding section.
We agree that this might be better suited as part of the methods section of the abstract. However, we do feel that sampling until saturation is reached is a crucial part of the used methods and therefore should be stated in the abstract. We have, however, moved the sentence to the 'participants' section. Page 2, lines 28-29: "Participants -Fifteen GPs were purposively sampled based on level of experience and practice characteristics until saturation was reached."
4.
Sentence starting "Deprescription was facilitated when GPs had experience with increased quality…" is a bit unclear. Should be clarified that GPs had experience with *patients* experiencing increased quality of life after deprescribing. The second half of this sentence after the colon is unclear, and I think ungrammatical, as the section after the colon is not an independent clause. Do you mean to say that the anticipated regret is GPs' fear of a stroke after deprescribing? I think this would make more sense if it read "and was withheld by anticipated regret should a patient suffer a stroke after deprescribing" or something similar. We had indeed struggled with describing these findings in the clearest way using as limited words as possible. We have incorporated the reviewers suggestions as follows: Page 2, lines 37-39: "Deprescription was facilitated when GPs' had experience with patients showing increased quality of life after deprescription and was withheld by anticipated regret (that is, GPs' fear of a stroke after deprescribing)." Introduction: 5.
General grammatical note -some missing possessive apostrophes. E.g. "Our primary aim was to explore GPs' routines", not "GPs routines." Thank you for this correction. We have adjusted it accordingly and also corrected it in our secondary aim. Page 5, lines 108-112: "Our primary aim was to explore GPs' routines and considerations on prescribing and deprescribing AHM in older people, to clarify the processes underlying current (de)prescribing practices. Our secondary aim was to assess GPs' judgement on usability of current guideline and their needs for future support in this decision making process, to help improve future guidelines on antihypertensive treatment in older people." Methods: 6.
I am unsure as to what you mean in saying that the interviews were performed using the COREQ criteria? These are criteria for reporting qualitative research, not conducting interviews. The COREQ criteria aided us in designing our qualitative study and in reporting our methods and findings. As these criteria are indeed not designed as methodological aid we have removed it from the methods section.
7.
Subheadings throughout this section would be helpful for the reader (i.e. Recruitment and sample, Data collection, Data analysis) We have added the subheadings 'Participants', 'Data collection' and 'Data analysis' to the methods section to improve readability.
8.
How were GPs approached to participate? Phone, face to face, etc? As you actually have quite a high participation rate for GP research this might be useful information for readers. GPs were approached by email and telephone. The number of GPs approached only contained those that replied on our request and did not include those that we could not reach. As this may give the wrong impression we clarified this as follows: Page 6, lines 124-125: "Of the 44 GPs approached, 15 agreed to participate, 13 could not be reached and 16 refused participation."
9.
How does Box 1 apply to the sentence that it follows? I gather that Box 1 justifies why you have chosen to conduct this study with GPs as opposed to say, cardiologists, but this is not explicit in the sentence that introduces Box 1. Box 1 was added to the manuscript to give the reader an impression of the primary care structure in the Netherlands to improve the interpretation of the results and generalizability to other health care settings. The placing of the reference to box 1 could indeed be viewed as somewhat odd in the methods section. We removed the reference to box 1 from this section and now only refer to it in the discussion when discussing the generalizability of our results.
10.
Last sentence of p6 -remove word 'at', 'transcribed by the interviewer verbatim' Thank you for the correction.
11.
Your COREQ checklist says that have included a statement of the theoretical framework/methodological approach on p7 but this is not discussed and should be included. The discussion of your thematic analysis process does not constitute a discussion of methodological approach, as thematic analysis can be used within many different methodologies. We inductively developed themes and subthemes (such as anticipated regret and patient preference) and structured these themes according to the change in antihypertensive medication that was discussed (starting, intensifying, continuing or deprescribing). We did not structure our analysis according to a theoretical framework, as we felt this might have restricted our interpretation of the data. We added the following sentence to the section on data analysis to make our used methodology more clear: Page 7, lines 148-149: "The (sub)themes derived from the codes were subsequently organised within the pre-specified structure on AHM (de)prescription: starting, intensifying, continuing and deprescribing."
12.
Was any software used in the coding process, even if it was simple software like Word and/or Excel? Or was your coding paper-based? Please specify. We used Microsoft Word for our coding process and Microsoft Excel to structure our codes by themes and subthemes. As we feel it is unlikely that the exact software we used biased our results (as previously elaborated on in response to reviewer 1), we feel it is justifiable to not include this detail to the methods section.
13.
Last sentence is missing a word between 'this' and 'underrepresented.' Thank you for noticing this error. There should indeed be 'is' in between the two words and we have added this to the sentence.
17.
For quotes in text and in Box 3 -although they are likely related, I think that stating the GPs' years of practice, rather than their age may be more interesting for the reader. In agreement with this comment, and the editorial remark that the characteristics may be identifiable, we have changed age to a range in years of experience.
18.
In section 'Continuation of treatment' what does 'global checks of AHM regimens' mean? With that phrase we meant to say that because of the time constraints GPs only very swiftly checked the prescribed medication as to whether no crucial errors were made. During this swift check no assessment is made as to whether medication is still appropriate. We rephrased it so this is more clear. Page 9, lines 206-209: "In combination with time constraints within the general practice organization, this prompted swift, global checks of AHM regimens only without room for an assessment whether the prescribed medication was still appropriate."
19.
In section 'Current guideline and future support', in the first sentence 'overthink' has a different meaning to what I believe you are implying (generally overthink has a negative meaning). I would suggest the use of 'reflect on decisions' rather than 'overthink.' Thank you for this suggestion. This nuance in wording is very helpful to correctly state our findings. We have changed it accordingly.
20.
The quotes used in this section are both from less experienced GPs. Was there any variation with regard to this theme between less and more experienced GPs? Our impression is that the GPs with less experience were more dependent on guidelines and could have felt a higher urgency for additional support. The GPs with more experience based their treatment decision more often on previous experience and did not feel the necessity to stick to the guidelines as strict as their younger colleagues. However, as we only had a small number of observations we feel insufficiently comfortable to state this in the manuscript.
21.
At the end of this section you discuss suggested ideas for future support. As these are in the Results I assume these suggestions come from your participants, could you make this explicit. Some issues with English expression/grammar throughout this section. Some suggested corrections 'may refrain from intensifying AHM in cases of frailty' not 'in case of frailty', 'supported by anticipated discomfort' not 'supported by the anticipating discomfort', 'Anticipated regret of a future stroke' not 'anticipated regret for stroke' (appears in both the first and final paragraphs of the Discussion) We have adapted these phrases accordingly.
23.
You mention the increased role of practice nurses in CVD prevention programs, could this be include as a possible avenue for future research in deprescribing practice in the Netherlands? From the interviews it was our impression that practice nurses do not facilitate (and may even be a barrier to) deprescription, as they work more strictly in line with the guidelines. As it requires an elaborate understanding of benefits and risks of medication, in our opinion, this should remain a task of the GPs as long as evidence remains limited and inconsistent. Only when future trials can give us clear indicators to deprescribe, this might also be something the practice nurse may support. As this is somewhat beyond the scope of the manuscript, we did not incorporate this comment in the manuscript.
24.
Just a suggestion, but a paper has come out since you submitted this for review which may provide something to your discussion of patient preferences and shared decision-making in deprescribing: Tables and Boxes: 25.
Title of Box 3 -suggestion to change to title to 'Quotes about patient cases…' rather than 'citations…' We changed citations to quotes in the title of box 2 (previous box 3).
VERSION 2 -REVIEW
REVIEWER
Bert Vaes KU Leuven, Belgium REVIEW RETURNED 14-Mar-2018
GENERAL COMMENTS
The paper was further improved. The authors have sufficiently answered the questions.
REVIEWER
Shannon McKinn
University of Sydney, Australia REVIEW RETURNED 20-Mar-2018
GENERAL COMMENTS
The authors have been thorough in their revisions and thoughtful in their responses. I have no further comments.
